Neuren Pharmaceuticals (ASX:NEU) Targets Global Expansion with Rising Royalties and Phase 3 Trial Plans

4 min read | June 25, 2025 09:59 PM AEST | By Team Kalkine Media

Google News:

Neuren Pharmaceuticals (ASX:NEU) Targets Global Expansion with Rising Royalties and Phase 3 Trial Plans — Image source: shutterstock

Recent News

Why Is Insider Activity Putting Lion Rock Minerals Back in Focus?

Should Investors Be Concerned About Insider Selling at Clever Culture...

Can Lendlease’s Australia-First Strategy Rewrite Its Future?

3 ASX ETFs That Could Shape the Next Decade

Make Kalkine Media
My Trusted Source

Highlights

JDO’s FY24 revenue from customer contracts fell by 8% YoY to AUD 213.2 million.

The company repurchased 4.08 million shares for AUD 49.998 million at prices between AUD 9.79–14.23.

NEU anticipates 2025 royalty growth from DAYBUE™ and plans Phase 3 NNZ-2591 trial by mid-year.

Neuren Pharmaceuticals Limited (ASX:NEU) is an ASX-listed company that develops therapies for neurological disorders, including FDA-approved DAYBUE™ for Rett syndrome and clinical-stage candidate NNZ-2591.

In the financial year 2024 (FY24), the company’s revenue from customer contracts fell by 8% YoY to AUD 213.2 million. FY24 Revenue was driven by increased DAYBUE™ royalties, milestone payments from sales thresholds, and proceeds from the sale of a priority review voucher. During the reported period, cash and short-term investments declined by 3% YoY to AUD 222.2 million, down from AUD 228.5 million in FY23. However, comprehensive income rose by 6% YoY to AUD 166.2 million, up from AUD 157.1 million.

At the end of FY24, cash balance stood at AUD 341 million, offering flexibility to company to advance its Phase 3 pipeline and international expansion strategy.

Business Update

Through an ASX announcement dated 16 June 2025, NEU announced that it completed an on-market buy-back of 4,076,150 shares, spending AUD 49.998 million between April and May 2025, with share prices ranging from AUD 9.79 to AUD 14.23.

At the annual general meeting held on 27 May 2025, the Chairman discussed NEU’s record FY2024 results, highlighting DAYBUE™ sales, NNZ-2591 trial progress, and the ongoing AUD 50 million buy-back, stating the company is positioned for sustained growth.

Company Outlook

NEU expects royalty growth in 2025 from DAYBUE™ on the back if increase in U.S. sales and launch of products in Canada, Europe, and Japan. A Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome is planned by mid-2025 after positive Phase 2 results.

The company targets global expansion through regulatory submissions for trofinetide in European and Japanese and Acadia’s access programs.

Share performance of NEU

NEU shares remained unchanged at AUD 12.540 per share on 25 June 2025. Over the past year, the stock has dropped 37.98%, with a 6.77% decline in the past month and 9.33% loss over the last nine months. In contrast, the stock has gained 5.11% over the past three months and 2.79% over six months.
The 52-week high for NEU is AUD 22.440, reached on 17 July 2024, and the 52-week low is AUD 8.610, recorded on 7 April 2025.

Support and Resistance Summary

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 25 June 2025. The reference data in this report has been partly sourced from EODHD/Others.

Technical Indicators Defined:

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.

Disclaimer

This article has been prepared by Kalkine Media, echoed on the website kalkinemedia.com/au and associated pages, based on the information obtained and collated from the subscription reports prepared by Kalkine Pty. Ltd. [ABN 34 154 808 312; AFSL no. 425376] on Kalkine.com.au (and associated pages). The principal purpose of the content is to provide factual information only for educational purposes. None of the content in this article, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video is or is intended to be, advisory in nature. The content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including but not limited to, in respect of any particular security, transaction, or investment strategy, and must not be relied upon by you as such. The content is provided without any express or implied warranties of any kind. Kalkine Media, and its related bodies corporate, agents, and employees (Kalkine Group) cannot and do not warrant the accuracy, completeness, timeliness, merchantability, or fitness for a particular purpose of the content or the website, and to the extent permitted by law, Kalkine Group hereby disclaims any and all such express or implied warranties. Kalkine Group shall NOT be held liable for any investment or trading losses you may incur by using the information shared on our website.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.